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Background. Chronic kidney disease has been shown to be
an independent risk factor for cardiovascular disease in high-
risk populations. However, this relationship is inconclusive in
community-based populations.
Methods. To clarify this issue, we followed 2634 community-
dwelling individuals without cardiovascular disease, aged
40 years or older, for 12 years and examined the relationship
between chronic kidney disease and the incidence of cardiovas-
cular disease.
Results. During the follow-up period, 99 subjects (56 men and
43 women) experienced coronary heart disease, 137 subjects
(60 men and 77 women) ischemic stroke, and 60 subjects (26 men
and 34 women) hemorrhagic stroke. In men, the age-adjusted
incidence of coronary heart disease was significantly higher in
subjects with chronic kidney disease than in those without it
(6.2 vs. 2.9 per 1000 person-years) (P < 0.05), but such a rela-
tionship was not observed with ischemic stroke. In contrast, in
women, the age-adjusted incidence of ischemic stroke was sig-
nificantly higher in subjects with chronic kidney disease than in
those without it (3.4 vs. 2.5) (P < 0.05), while that of coronary
heart disease was not. Chronic kidney disease was not found
to be associated with the incidence of hemorrhagic stroke. In
multivariate analysis, even after adjustments for traditional and
nontraditional cardiovascular disease risk factors, chronic kid-
ney disease was found to be an independent risk factor for the
occurrence of coronary heart disease in men [hazard ratio (HR),
2.26; 95% CI, 1.06-4.79], and for the occurrence of ischemic
stroke in women (HR, 1.91; 95% CI, 1.15-3.15).
Conclusion. Our findings suggest that chronic kidney disease
is an independent risk factor for the occurrence of cardiovascu-
lar disease in the general Japanese population.
Patients with end-stage renal disease (ESRD) are at a
much higher risk of cardiovascular disease than the gen-
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eral population, with the cardiovascular mortality rate
in patients with ESRD being 10 to 20 times higher than
that in general populations [1]. In 1998, the National Kid-
ney Foundation Task Force on Cardiovascular Disease in
Chronic Renal Disease issued a report emphasizing the
high risk of cardiovascular disease not only in patients
with ESRD, but also in those with chronic kidney dis-
ease [2]. The reason for the higher risk of cardiovascular
disease in individuals with chronic kidney disease is not
entirely clear, but is thought to be related in part to the
high prevalence of traditional risk factors for cardiovas-
cular disease in individuals with reduced kidney function
[3]. Thus, interest has grown recently in the examination
of kidney disease itself as an independent risk factor for
cardiovascular disease [4, 5]. Some studies of high-risk
populations, such as those who already have cardiovas-
cular disease or who have several coexisting cardiovas-
cular risk factors, have found decreased kidney function
to be an independent risk factor for cardiovascular dis-
ease [6–20]. In prospective studies of general populations,
however, the relationships between the levels of kidney
function and cardiovascular disease outcomes have been
inconclusive [21–25].
In the present article, we reported the findings of a
prospective survey examining the relationships between
cardiovascular disease and the incidence of coronary
heart disease and stroke in all study subjects of a general
Japanese population, taking other traditional and non-
traditional risk factors into account.
METHODS
Study population
The Hisayama Study, an epidemiologic study of cere-
brovascular and cardiovascular diseases, was established
in 1961 in Hisayama, a suburban community adjacent to
Fukuoka City, a metropolitan area on Kyushu Island in
southern Japan. Hisayama’s population of approximately
7000 has been stable for 40 years. Full community surveys
of the residents have been repeated since 1961 [26]. In
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1988, a screening survey for the present study was per-
formed in Hisayama. A detailed description of this sur-
vey was published previously [27]. Briefly, a total of 2736
participants aged 40 years or older (80.7% of the total
population of this age group) consented to participate
in the examination and underwent a comprehensive as-
sessment. We excluded from the study 99 subjects with a
history of myocardial infarction or stroke, as determined
by a questionnaire and medical records. In addition, af-
ter the exclusion of one subject without a blood sample
and two subjects who were on predialysis [glomerular fil-
tration rate (GFR) <15 mL/min/1.73 m2], the remaining
2634 individuals (1110 men and 1524 women) were en-
rolled in this study.
Follow-up
The subjects were followed prospectively from Decem-
ber 1988 to November 2000 by repeated health examina-
tions. The health examinations were conducted yearly,
and the participation rate was approximately 50% to
80%. Health status was checked yearly by mail or tele-
phone for any subjects who did not undergo a regular
examination that year or who had moved out of town.
We also established a daily monitoring system among the
study team and local physicians or members of the town’s
Health and Welfare Office. When a subject died, an au-
topsy was performed at the Department of Pathology of
Kyushu University. During the follow-up period, 485 sub-
jects died, of whom 366 (75.5%) underwent autopsy. Only
one subject was lost to follow-up.
Definition of chronic kidney disease
GFR was estimated using the simplified prediction
equation derived from the Modification of Diet in Renal
Disease (MDRD) Study [28] and given by the following
equation:
GFR(mL/min/1.73m2) = 170
× [serum creatinine (mg/dL)]−0.999
× [age (years)]−0.176
× [serum urea nitrogen (mg/dL)]−0.170
× [serum albumin (g/dL)]0.318 × [0.762if female]
GFR <60 mL/min/1.73 m2 was defined as chronic kid-
ney disease according to the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative guidelines
[29].
Definition of cardiovascular events
The criteria for a diagnosis of coronary heart disease
included first-ever acute myocardial infarction, silent my-
ocardial infarction, or sudden cardiac death within 1
hour after the onset of acute illness [30]. Acute my-
ocardial infarction was diagnosed when a subject met
at least two of the following criteria: (1) typical symp-
toms, including prolonged severe anterior chest pain;
(2) abnormal cardiac enzymes more than twice the up-
per limit of the normal range; (3) evolving diagnos-
tic electrocardiogram (ECG) changes; or (4) morpho-
logic changes, including local asynergy of cardiac wall
motion on echocardiography, persistent perfusion defect
on cardiac scintigraphy, or myocardial necrosis or scars
>1 cm long accompanied by coronary atherosclerosis
at autopsy. Silent myocardial infarction was defined as
myocardial scarring without any historical indication of
clinical symptoms or abnormal cardiac enzyme changes.
During the follow-up period, we identified 99 first-ever
coronary heart disease events (56 men and 43 women).
Stroke was defined as a sudden onset of nonconvulsive
and focal neurologic deficit persisting for >24 hours. The
diagnosis of stroke and the determination of its patho-
logic type were based on the clinical history, neurologic
examination, all available clinical data, including brain
computed tomography (CT)/magnetic resonance imag-
ing (MRI), and autopsy findings. Stroke was classified as
either ischemic or hemorrhagic [30]. Hemorrhagic stroke
included cerebral hemorrhage and subarachnoid hem-
orrhage. During the follow-up period, we identified 197
first-ever stroke events (86 men and 111 women). These
were divided into 137 cases of ischemic stroke (60 men
and 77 women) and 60 cases of hemorrhagic stroke (26
men and 34 women).
Risk factors
At the baseline examination, each participant com-
pleted a self-administered questionnaire covering med-
ical history, antihypertensive treatment, smoking habits,
and alcohol intake. The completed questionnaire was
checked by trained interviewers at the screening. The
latter three variables were classified as either current ha-
bitual use or not. Blood pressures were measured three
times, after at least 5 minutes of rest, using a standard
mercury sphygmomanometer with the subject in the sit-
ting position. The mean of three measurements was used
for the analysis. Hypertension was defined as blood pres-
sure ≥140/90 mm Hg and/or current use of antihyperten-
sive agents. Body height and weight were measured in
light clothing without shoes, and the body mass index
(kg/m2) was calculated. Electrocardiogram (ECG) ab-
normalities were defined as left ventricular hypertrophy
(Minnesota code, 3-1) and/or ST depression (Minnesota
code, 4-1, 2, 3). The study physicians performed a physical
examination of each participant and rechecked his or her
medical history to improve the precision of the informa-
tion. Blood samples were collected after an overnight fast
for the determination of serum creatinine, urea nitrogen,
albumin, hemoglobin A1c, and lipids. These specimens
were assayed within 24 hours. A portion of the serum
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Table 1. Age-adjusted mean values or frequencies of potential risk factors and laboratory variables according to kidney function by gender
Men Women
CKD (−) CKD (+) CKD (−) CKD (+)
Variables (N = 1051) (N = 59) (N = 1313) (N = 211)
Age years 58 ± 11 73 ± 11a 58 ± 11 71 ± 11a
Serum urea nitrogen mmol/L 5.5 ± 1.3 7.2 ± 1.4a 5.2 ± 1.2 6.4 ± 1.3a
Creatinine lmol/L 94.7 (75.6-118.6) 127.8 (101.1-161.5)a 78.4 (63.2-97.2) 98.9 (78.7-124.2)a
Systolic blood pressure mm Hg 135 ± 19 140 ± 20 132 ± 20 138 ± 21a
Diastolic blood pressure mm Hg 80 ± 11 82 ± 12 76 ± 11 77 ± 12
Antihypertensive medication% 11.8 19.8a 11.5 18.9a
Hypertension% 42.8 60.1b 32.8 39.4a
ECG abnormalities% 19.0 17.8 12.5 9.3
Albumin g/L 43 ± 2 42 ± 2 42 ± 2 42 ± 2
Diabetes mellitus% 14.2 17.6 8.6 6.8
Hemoglobin A1c% 5.6 ± 0.8 5.6 ± 0.8 5.5 ± 0.7 5.6 ± 0.8
Total cholesterol mmol/L 5.06 ± 1.06 5.46 ± 1.11a 5.51 ± 1.07 5.69 ± 1.14b
Triglycerides mmol/L 1.31 (0.41-4.16) 1.43 (0.43-4.77) 1.06 (0.42-2.69) 1.12 (0.42-3.00)
HDL cholesterol mmol/L 1.25 ± 0.31 1.25 ± 0.32 1.33 ± 0.30 1.33 ± 0.32
Body mass index kg/m2 22.7 ± 2.9 23.1 ± 3.0 22.9 ± 3.3 23.0 ± 3.5
Total homocysteine lmol/L 10.4 ± 5.3 11.4 ± 5.6a 8.0 ± 3.7 9.8 ± 4.0a
HS-CRP mg/L 0.52 (0.02-11.50) 0.48 (0.02-12.05) 0.37 (0.02-7.69) 0.36 (0.01-8.81)
Smoking habits% 51.2 30.0 7.0 7.7
Alcohol intake% 62.0 46.6 9.7 2.9
Menopause% — — 64.0 67.8
Abbreviations are: CKD, chronic kidney disease; ECG, electrocardiogram; HDL, high-density lipoprotein; HS-CRP, high-sensitivity C-reactive protein.
Age is not age-adjusted. Hypertension was defined as blood pressure = 140/90 mm Hg and/or current use of antihypertensive agents. Diabetes mellitus was defined
according to the criteria recommended by the American Diabetes Association by a 75 g oral glucose tolerance test in 2450 subjects (93.0%), and by a fasting and
postprandial glucose concentration in 184 remainders, in addition to a medical history of diabetes. Geometric mean values and 95% confidence intervals of creatinine,
triglycerides, and high-sensitivity C-reactive protein are shown due to the skewed distribution. Values are means ± standard deviations or frequencies.
aP < 0.01; bP < 0.05 vs. CKD (−).
was stored at −20◦C until used in the measurement of
total homocysteine and high-sensitivity C-reactive pro-
tein (HS-CRP). Serum creatinine concentrations were
measured by Jaffe´ method. Hemoglobin A1c levels were
measured by the high-performance liquid chromatogra-
phy (HPLC) method. The total cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglycerides were all
determined enzymatically. Diabetes mellitus was defined
according to the criteria recommended by the American
Diabetes Association [31] by a 75 g oral glucose tolerance
test in 2450 subjects (93%), and by fasting and postpran-
dial glucose concentrations in 184 remainders, in addition
to a medical history of diabetes. Frozen serum samples
were thawed and assayed for serum total homocysteine
levels by the HPLC method and for HS-CRP by particle-
enhanced technology on the Dade Behring BN II neph-
elometer (Dade Behring, Tokyo, Japan). A high level of
HS-CRP was defined as that in the 75th percentile or
higher for serum HS-CRP in either gender.
Statistical analysis
The SAS software package was used to perform all
statistical analyses. Serum creatinine, triglycerides, and
HS-CRP were transformed into logarithms to improve
the skewed distribution. The relationships between the
kidney-function category and relevant factors were tested
with adjustments for age by covariance analysis or the
Mantel-Haenszel chi-square test using 10-year age group-
ings as appropriate. The incidences of cardiovascular dis-
ease were calculated by the person-year method and
adjusted for the age distribution of the World Health
Organization standard population in 1998 by the direct
method. Differences in incidence between the kidney
function categories were tested by the Cox proportional
hazards regression analysis after adjustment for age. The
age- or multivariate-adjusted hazard ratios (HRs) and
95% confidence intervals (CIs) were also estimated with
the use of the Cox proportional hazards model. In the
multivariate analysis, we selected previously reported tra-
ditional or nontraditional cardiovascular disease risk fac-
tors [3] as confounding factors, and used the stepwise
method with P < 0.2 required for entering or remaining
in the model. We confirmed the assumption of the propor-
tional hazards model, since the log-log survivor functions
by the kidney function were found to be parallel. P < 0.05
was considered statistically significant in all analyses.
RESULTS
Table 1 shows the baseline clinical and demographic
characteristics of the study subjects according to kidney
function by gender. In either gender, the subjects with
chronic kidney disease were significantly older than those
without it. Thus, the mean values or frequencies of other
variables were adjusted for age. The mean values of serum
urea nitrogen and creatinine were significantly higher in
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Table 2. Age-standardized incidence rates of cardiovascular disease according to kidney function by gender
Men Women
Person-years No. of Age-standardized Person-years No. of Age-standardized
at risk events incidence rate at risk events incidence rate
Cardiovascular disease
CKD (−) 10,997 117 8.3 14,624 98 4.8
CKD (+) 441 17 10.7 1991 43 6.7a
Coronary heart disease
CKD (−) 11,284 45 2.9 14,929 28 1.3
CKD (+) 460 11 6.2a 2076 15 2.7
Ischemic stroke
CKD (−) 11,885 56 3.8 15,801 50 2.5
CKD (+) 485 4 3.1 2131 27 3.4a
Hemorrhagic stroke
CKD (−) 11,885 23 1.9 15,801 30 1.4
CKD (+) 485 3 1.2 2131 4 0.8
Abbreviations are: CKD, chronic kidney disease; Incidence rate, per 1000 person-years.
aP < 0.05 vs. CKD (−).
Table 3. Age- or multivariate-adjusted analysis for occurrence of cardiovascular disease according to kidney function for men
Hazard ratio (95% confidence interval)
Model 1 Model 2 Model 3
Cardiovascular disease
CKD (−) 1.00 1.00 1.00
CKD (+) 1.45 (0.85–2.50) 1.29 (0.74–2.25) 1.32 (0.76–2.30)
Coronary heart disease
CKD (−) 1.00 1.00 1.00
CKD (+) 2.45 (1.19–5.03)a 2.14 (1.01–4.52)a 2.26 (1.06–4.79)a
Ischemic stroke
CKD (−) 1.00 1.00 1.00
CKD (+) 0.62 (0.22–1.77) 0.56 (0.20–1.61) 0.54 (0.19–1.53)
Hemorrhagic stroke
CKD (−) 1.00 1.00 1.00
CKD (+) 1.40 (0.39–5.01) 1.11 (0.29–4.21) 1.09 (0.29–4.13)
CKD is chronic kidney disease. Model 1 is adjusted for age. Model 2 is adjusted for age, systolic blood pressure, antihypertensive medication, electrocardiogram
abnormalities, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, triglycerides, body mass index, smoking habits, and alcohol intake. Model 3 is
adjusted for confounding factors used in the model 2, total homocysteine, and high-sensitivity C-reactive protein.
aP < 0.05 vs. CKD (−).
both male and female subjects with chronic kidney dis-
ease, as determined by the criteria. For both genders, sub-
jects with chronic kidney disease had higher mean values
of systolic blood pressure and higher frequencies of an-
tihypertensive medication and hypertension. The mean
total cholesterol and total homocysteine levels were also
significantly higher in subjects with chronic kidney dis-
ease than in those without it in either gender. The mean
values or frequencies of other potential risk factors did
not differ between the two kidney function groups in ei-
ther gender.
The age-standardized incidence rates of cardiovascu-
lar disease in each of the kidney function groups are
shown by gender in Table 2. The cardiovascular disease
incidence was higher in the subjects with chronic kidney
disease than in those without it in either gender, but the
difference was statistically significant only for women.
The incidence of coronary heart disease was twice as high
in men with chronic kidney disease as in men without it
(6.2 vs. 2.9 per 1000 person-years) (P < 0.05), while the
incidence of stroke did not differ significantly between
men with chronic kidney disease and men without it. In
contrast, in women the incidence of ischemic stroke was
significantly higher in subjects with chronic kidney dis-
ease (3.4 vs. 2.5) (P < 0.05), while the incidence of coro-
nary heart disease did not differ significantly between
women with chronic kidney disease and women without
it. Chronic kidney disease was not associated with hem-
orrhagic stroke in either gender.
Age- or multivariate-adjusted HRs of chronic kidney
disease for the occurrence of cardiovascular disease were
estimated for men (Table 3) and women (Table 4). The
age-adjusted analysis showed that chronic kidney disease
was a significant risk factor for coronary heart disease in
men and for ischemic stroke in women (model 1). These
relationships remained substantially unchanged even
after adjustments for other traditional cardiovascular
diseases risk factors, such as systolic blood pressure, anti-
hypertensive medication, ECG abnormalities, diabetes,
total cholesterol, HDL cholesterol, triglycerides, body
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Table 4. Age- or multivariate-adjusted analysis for occurrence of cardiovascular disease according to kidney function for women
Hazard ratio (95% confidence interval)
Model 1 Model 2 Model 3
Cardiovascular disease
CKD (−) 1.00 1.00 1.00
CKD (+) 1.55 (1.06–2.28)a 1.62 (1.10–2.39)a 1.62 (1.10–2.39)a
Coronary heart disease
CKD (−) 1.00 1.00 1.00
CKD (+) 1.58 (0.81–3.08) 1.55 (0.79–3.06) 1.55 (0.79–3.05)
Ischemic stroke
CKD (−) 1.00 1.00 1.00
CKD (+) 1.84 (1.12–3.04)a 1.91 (1.15–3.16)a 1.91 (1.15–3.15)a
Hemorrhagic stroke
CKD (−) 1.00 1.00 1.00
CKD (+) 0.56 (0.19–1.67) 0.56 (0.19–1.67) 0.58 (0.19–1.73)
CKD is chronic kidney disease. Model 1 is adjusted for age. Model 2 is adjusted for age, systolic blood pressure, antihypertensive medication, electrocardiogram
abnormalities, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, triglycerides, body mass index, smoking habits, and alcohol intake. Model 3 is
adjusted for confounding factors used in the model 2, total homocysteine, and high-sensitivity C-reactive protein.
aP < 0.05 vs. CKD (−).
Table 5. Age- and gender-adjusted or multivariate-adjusted hazard ratio for occurrence of cardiovascular disease according to kidney function by
status of hypertension or high-sensitivity C-reactive protein (HS-CRP) levels in 2634 subjects
Age- and sex-adjusted Multivariate-adjusted
Population at risk No. of events hazard ratio (95% CI) hazard ratio (95% CI)
Hypertension (−)
CKD (−) 1448 83 1.00 1.00
CKD (+) 91 9 1.03 (0.50-2.13) 1.11 (0.53-2.29)a
Hypertension (+)
CKD (−) 916 132 1.00 1.00
CKD (+) 179 51 1.54 (1.08-2.20)b 1.63 (1.14-2.33)a,c
Low levels of HS-CRP
CKD (−) 1806 144 1.00 1.00
CKD (+) 178 39 1.63 (1.10-2.41)b 1.59 (1.07-2.36)b,d
High levels of HS-CRP
CKD (−) 558 71 1.00 1.00
CKD (+) 92 21 1.49 (0.88-2.54) 1.46 (0.84-2.52)d
Abbreviations are: CKD, chronic kidney disease; CI, confidence interval. Hypertension was defined as blood pressure ≥140/90 mm Hg and/or current use of
antihypertensive agents. A high level of high-sensitivity C-reactive protein was defined as that in the 75th percentile or higher for serum high-sensitivity C-reactive
protein in either gender.
aAdjusted for age, gender, electrocardiogram abnormalities, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, triglycerides, body mass index,
smoking habits, alcohol intake, total homocysteine, and high-sensitivity C-reactive protein.
bP < 0.05 vs. CKD (−).
cP < 0.01.
dAdjusted for age, gender, systolic blood pressure, antihypertensive medication, electrocardiogram abnormalities, diabetes mellitus, total cholesterol, high-density
lipoprotein cholesterol, triglycerides, body mass index, smoking habits, alcohol intake, and total homocysteine.
mass index, smoking habits, and alcohol intake (model
2). Furthermore, even after controlling for nontraditional
cardiovascular disease risk factors, including total homo-
cysteine and HS-CRP, chronic kidney disease was found
to be an independent risk factor for the occurrence of
coronary heart disease in men (model 3) (HR 2.26 and
95% CI 1.06-4.79) (P < 0.05) and for the occurrence of
ischemic stroke in women (HR 1.91 and 95% CI 1.15-
3.15) (P < 0.05).
We examined the associations between GFR as a con-
tinuous variable and cardiovascular disease outcomes.
This analysis showed the significant inverse association
between GFR levels and the risk of coronary heart dis-
ease (CHD) events in men (for a decrease in GFR by
10 mL/min/1.73 m2) (HR 1.30 and 95% CI 1.01-1.67)
(P < 0.05), even after adjustments for the traditional and
nontraditional cardiovascular disease risk factors named
above. A similar tendency was observed for the risk of is-
chemic stroke in women (HR 1.26 and 95% CI 0.98-1.60)
(P = 0.07).
There were no significant interactions between kid-
ney function and risk factors, including hypertension,
diabetes, smoking habits, ECG abnormalities, total
cholesterol, triglycerides, HDL cholesterol, total homo-
cysteine, and HS-CRP in the occurrence of cardiovascular
disease.
Because hypertension and inflammation are strong risk
factors for cardiovascular disease, we examined the ef-
fects of chronic kidney disease on the occurrence of car-
diovascular disease stratified by hypertension or levels
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of HS-CRP. As shown in Table 5, the age- and gender-
adjusted or multivariate-adjusted HR of cardiovascu-
lar disease was significantly higher in the subjects with
chronic kidney disease than in those without it in the hy-
pertensive group, but not in the normotensive group. On
the other hand, chronic kidney disease is a risk factor
for cardiovascular disease events regardless of HS-CRP
levels, though it is not significant in high levels of HS-
CRP, probably because of the small number of subjects
in the present study.
DISCUSSION
In a prospective study of a community-dwelling
Japanese population, we demonstrated chronic kidney
disease to be an independent predictor of coronary heart
disease events in men and of the occurrence of cardio-
vascular disease and ischemic stroke in women. To our
knowledge, this is the first population-based prospective
study on the association between chronic kidney disease
and cardiovascular disease in Japan.
The reduction in kidney function has consistently been
found to be an independent risk factor for cardiovascular
disease and all-cause mortality in patients after coronary
events [6, 7] in those undergoing coronary interventions
[8, 9], in patients with heart failure [10–12], in patients
with hypertension [13–15] or diabetes [16], and in elderly
subjects [17–20]. This relationship has been inconsistent,
however, in prospective studies of general populations. In
the Atherosclerosis Risk in Communities (ARIC) Study
[21] and the Second National Health and Nutrition Ex-
amination Survey (NHANES II) [22], reduced kidney
function was found to be an independent risk factor
for cardiovascular disease events or all-cause mortality.
These findings are in accord with those of the present
study. These associations were not observed, however, in
the Framingham Study [23] and the First National Health
and Nutrition Examination Survey (NHANES I) [24].
Differences in the study population are a possible rea-
son for this discrepancy; for example, African Americans
were part of the ARIC Study but not of the Framingham
Study. Another possible reason is that serum creatinine,
which was used as a measure of renal function in both
the Framingham Study [23] and the NHANES I [24], is
less sensitive than estimated GFR, which was used in our
study as well as in the ARIC and NHANES II Studies, in
the detection of small differences in the levels of kidney
function; thus, an association in low-risk populations may
be less detectable when serum creatinine is used. When
we examined the associations between serum creatinine
and cardiovascular disease events in our population, we
found no significant associations between these parame-
ters, indicating that GFR is a better predictor of cardio-
vascular disease events than serum creatinine.
There are several possible explanations for the inde-
pendent association of chronic kidney disease with car-
diovascular disease outcome [5]. Reduced renal function
is associated with a high prevalence of traditional car-
diovascular disease risk factors, such as aging, diabetes,
smoking habits, elevated blood pressure, and total choles-
terol levels, decreased HDL cholesterol levels, and left
ventricular hypertrophy by ECG [3]. In addition, a re-
duced GFR may be associated with increased levels of
nontraditional cardiovascular disease risk factors, such
as total homocysteine, inflammation, production of nitric
oxide, oxidative stress, and thrombogenic factors [3, 32].
These factors could increase the risk of cardiovascular
disease in subjects with chronic kidney disease. In our
subjects, however, the association between chronic kid-
ney disease and the incidence of cardiovascular disease
remained significant even after adjustment for the tradi-
tional cardiovascular disease risk factors named above
and some of the nontraditional cardiovascular disease
risk factors, including total homocysteine and HS-CRP
levels. Further investigation is needed into the role of
other nontraditional cardiovascular disease risk factors
in the occurrence of cardiovascular disease among sub-
jects with chronic kidney disease. Another possible ex-
planation for the chronic kidney disease-cardiovascular
disease association is that reduced renal function may be a
marker of vascular disease. In our previous autopsy study
of deceased Hisayama residents, the development of re-
nal arteriosclerosis and glomerular sclerosis was found
to be closely associated with reduced GFR in both gen-
ders [33]. It is well recognized that renal arteriosclerosis
and glomerular sclerosis are closely related to systemic
atherosclerosis [34, 35], suggesting an increased risk of
cardiovascular disease in subjects with chronic kidney dis-
ease.
In the stratified analysis, we found that chronic kid-
ney disease was a significant predictor of cardiovascu-
lar disease in the hypertensive subjects. Previous clini-
cal studies have also found that reduced GFR is a risk
factor for cardiovascular disease events in patients with
hypertension [17–19]. Because hypertension is a strong
risk factor for the progression of systemic atherosclerosis,
it is reasonable to consider that subjects with hyperten-
sion already have vascular injuries to some extent. Our
findings, together with those of the other studies, sug-
gest that chronic kidney disease is a marker of advanced
vascular injuries in high-risk populations, or that chronic
kidney disease–related metabolic disorders, such as dys-
lipidemia, oxidative stress, or calcium-phosphate abnor-
mality, accelerate the progression of preexisting vascu-
lar injuries [36]. The reason why chronic kidney dis-
ease was not a significant risk factor for cardiovascular
disease in the normotensive subjects may be that the
causes of chronic kidney disease among normotensives,
such as primary renal disease, are not directly related
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to atherosclerosis. In addition, chronic kidney disease–
related metabolic disorders may affect normal or mildly
injured vessels to a lesser extent in normotensives than
in hypertensives, and therefore, the 12-year follow-up pe-
riod of our study may be insufficient to allow for the oc-
currence of cardiovascular disease.
In the present study, chronic kidney disease was
found to be an independent risk factor in men for the
occurrence of coronary heart disease but not of ischemic
stroke. A possible reason for this discrepancy is compe-
tition among causes of cardiovascular disease, whereby
our men with chronic kidney disease were more likely
to suffer from coronary heart disease than from ischemic
stroke, thereby causing possible censorship of data due
to coronary death. Also, risk factors may have been mod-
ified in response to medical advice and treatment af-
ter coronary heart disease events, which would probably
have weakened the association between chronic kidney
disease and ischemic stroke. In contrast, for women with
chronic kidney disease, an opposite phenomenon was ob-
served: the risk of ischemic stroke was significantly ele-
vated, while the risk of coronary heart disease was not.
This phenomenon is likely due to both inadequate sta-
tistical power and to the low risk of coronary heart dis-
ease in Japanese women. Some reports indicate a higher
risk of stroke in women [37, 38]. Di Tullio et al [38] have
shown that smaller aortic plaques are significantly associ-
ated with ischemic stroke in women but not in men. This
gender difference may be a consequence of the effects of
hypercoagulable states [39, 40], lipid abnormalities [41],
or gonadal steroids [42–44] in women. Further studies
are necessary to elucidate these gender differences in
detail.
Several limitations of our study should be discussed.
The primary limitation is the small numbers of both sub-
jects and cardiovascular disease events in the study popu-
lation. Thus, the generalizability of the study results may
be somewhat limited. Nonetheless, we believe that the
findings of our study represent the actual association be-
tween chronic kidney disease and cardiovascular disease
outcomes, since we used a highly accurate method of de-
termining all cardiovascular disease cases.
The second limitation is that our results might be bi-
ased, because almost 20% of the target population did not
participate. At baseline, the mean age of subjects who did
not participate was significantly lower than that of sub-
jects who did participate (53 vs. 60 years old), and the
proportion of men was significantly higher among non-
participants (57% vs. 42%). Unfortunately, we could not
obtain information on other risk factors among the non-
participants. However, it is generally agreed that an ac-
ceptable participation rate in a population-based study
(i.e., a rate that practically eliminates the threat of selec-
tion bias attributable to nonparticipants) is above 70% of
the target population [45, 46]. Because of the high partic-
ipation rate in our study (81%), this bias did not seem to
have the potential to alter our findings.
The third limitation is that our GFR estimates, which
were made using the simplified prediction equation de-
rived from the MDRD Study and that were based on a
single blood sample, might not be sufficiently correct, al-
though this prediction equation, among other equations
of its type, is considered to be the most precise estimate
of GFR [28]. In addition, a recent report has shown that
repeated measurements of serum creatinine are neces-
sary to correct within-person measurement variations of
serum creatinine [47], suggesting that some nondifferen-
tial misclassifications of cases with chronic kidney disease
may have occurred in our study. Given that this limita-
tion can reduce the impact of chronic kidney disease, the
true association may be stronger than that shown in our
findings.
The fourth limitation is that we have no information re-
garding the severity or duration of hypertension or other
cardiovascular disease risk factors. The fifth limitation
is that we also could not provide information regarding
the type or number of antihypertensive drugs, medica-
tion compliance, and blood pressure control. Although
ECG abnormalities, which reflect target-organ damage
from hypertension or other risk factors, were used as a
confounding factor in the multivariate analysis, these lim-
itations may reduce the accuracy of our findings to some
extent. Thus, they have the potential to alter our findings,
but they are not likely to do so.
The sixth limitation is that our subjects with chronic
kidney disease may have undergone more intense med-
ical surveillance than those without it, resulting in a
surveillance bias. However, diagnostic procedures such
as echocardiography and scintigraphy were usually per-
formed in subjects who presented symptoms or clinical
signs of cardiac ischemia, but were not performed in sub-
jects who did not present cardiac symptoms, even if they
had chronic kidney disease. Brain CT/MRI was taken
in the similar situation. In addition, as described in the
Methods section, the diagnosis of cardiovascular disease
was in principle based on the acute events of heart and
brain attack. We performed almost the same follow-up
surveys on all study subjects regardless of the presence
or absence of chronic kidney disease. The mean number
of health investigations was similar for subjects with or
without chronic kidney disease in men (4 ± 4 times in
subjects with chronic kidney disease vs. 5 ± 4 times in
subjects without chronic kidney disease) and in women
(5 ± 4 times vs. 6 ± 4 times). Furthermore, health status
was checked yearly by mail or telephone for any sub-
jects who did not undergo a regular examination that
year or who had moved out of town. Thus, subjects with
chronic kidney disease are considered not to have under-
gone more intense medical surveillance, so the potential
for such bias seems to be negligible.
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CONCLUSION
Chronic kidney disease was found to be an inde-
pendent risk factor for the incidence of cardiovascular
disease in a general Japanese population. Our findings
suggest that subjects with chronic kidney disease should
be considered a high-risk population for cardiovascu-
lar disease and be recommended for more intensive
preventive management of cardiovascular disease, in-
cluding active detection and strict treatment of cardio-
vascular risk factors. An additional clinical intervention
trial is needed to evaluate preventive measures of cardio-
vascular disease in subjects with chronic kidney disease.
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